Pyxis Oncology Inc. Common Stock (PYXS)
Stock · NASDAQ · Health Care
$1.7as of 10/16/2026
Price chart
Active signals
PYXS Signal Track Record
How signals performed across all stocks →What PYXS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -1.5% | 49% | September 30, 2026 |
| Bollinger Band Breakout | 21 | +1.8% | 52% | September 4, 2026 |
| Bollinger Band Breakdown | 17 | -6.2% | 24% | September 30, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +9.9% | 71% | October 2, 2026 |
| Any 20-session window (baseline) | -1.7% | 47% |
Computed by MarketWall from daily closing prices since July 26, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PYXS
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 56
- Website
- pyxisoncology.com/
Fundamentals
- 1-day range
- $1.66$1.79
- Market cap
- $237.58M
- P/E (trailing)
- —
- P/E (forward)
- -1.52
- EPS (trailing)
- $-1.28
- Dividend yield
- —
- Beta
- 1.36
- Avg. volume
- 1.27M
How Pyxis Oncology Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
Pyxis Oncology Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PYXSPyxis Oncology Inc. Common Stock$1.68▼ 6.67%Market cap $237.58MP/E —$1.03$5.55
- ACIUAC Immune SA Common Stock$2.39▼ 2.45%Market cap $236.11MP/E —$2.1$4
- CAPRCapricor Therapeutics Inc. Common Stock$6.71▼ 7.70%Market cap $242.07MP/E —$2.96$40.37
- SLGLSol-Gel Technologies Ltd. Ordinary Shares$64.25▼ 6.48%Market cap $244.18MP/E —$28.81$97.97
- SIGASIGA Technologies Inc. Common Stock$3.17▼ 0.63%Market cap $223.78MP/E —$2.83$8.55
- WHWKWhitehawk Therapeutics Inc. Common Stock$2.89▼ 4.93%Market cap $252.78MP/E —$1.97$5.5
- MGNXMacroGenics Inc. Common Stock$3.25▼ 3.56%Market cap $254.89MP/E —$1.29$5.08
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PYXS Pyxis Oncology Inc. Common Stock | $237.58M | — | $1.68 | ▼ 6.67% | $1.03$5.55 |
| ACIU AC Immune SA Common Stock | $236.11M | — | $2.39 | ▼ 2.45% | $2.1$4 |
| CAPR Capricor Therapeutics Inc. Common Stock | $242.07M | — | $6.71 | ▼ 7.70% | $2.96$40.37 |
| SLGL Sol-Gel Technologies Ltd. Ordinary Shares | $244.18M | — | $64.25 | ▼ 6.48% | $28.81$97.97 |
| SIGA SIGA Technologies Inc. Common Stock | $223.78M | — | $3.17 | ▼ 0.63% | $2.83$8.55 |
| WHWK Whitehawk Therapeutics Inc. Common Stock | $252.78M | — | $2.89 | ▼ 4.93% | $1.97$5.5 |
| MGNX MacroGenics Inc. Common Stock | $254.89M | — | $3.25 | ▼ 3.56% | $1.29$5.08 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&DSeekingAlpha · 10/4/2026
- Pyxis Oncology Announces Closing of Up to $282.6 Million Public OfferingYahoo · 10/2/2026
- Let's take a look at the stocks that are in motion in today's session.ChartMill · 9/30/2026
- Which stocks are gapping on Wednesday?ChartMill · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 9/30/2026
- Wednesday's pre-market session: top gainers and losersChartMill · 9/30/2026
- 12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga · 9/30/2026
- Pyxis Oncology Prices $110M Offering Of 36,047,919 Shares At $2.90 With Common Warrants For 49,310,352 Shares At $3.50 Exercise Pricebenzinga · 9/30/2026
- Pyxis Oncology Announces Pricing of Up to $282.6 Million Public OfferingYahoo · 9/30/2026
Insider Activity
Insider Actions →- GordonMD Global Investments LP · October 1, 2026 · Buy7.17M
- GordonMD Global Investments LP · October 1, 2026 · Buy7.55M
- GordonMD Global Investments LP · October 1, 2026 · Buy5.52M
- Civik Thomas · September 4, 2026 · Grant2.50M
- Dupont Jakob · August 20, 2026 · Grant46.0K
- Civik Thomas · August 12, 2026 · Grant251.0K
- Dupont Jakob · June 30, 2026 · Option Exercise35.0K @ $1.6
- Dupont Jakob · June 30, 2026 · Sale35.0K @ $3.06
Institutional Ownership
March 31, 2026
- Total shares held
- 27.37M
- Total value held
- $40.01M
- Institutional holders
- 74
- Unknown7.03M
- Unknown5.00M
- Unknown4.12M
- Unknown2.03M
- Unknown1.01M
- Unknown896.3K
- Unknown888.7K
- Unknown788.8K
- Unknown598.1K
- Unknown503.2K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops
Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.
Pyxis Oncology Announces $282.6M Public Offering, Stock Drops. Pyxis Oncology disclosed it will price a public offering of up to $282.6 million, including common stock and warrants. The announcement was followed by a decline in the stock price in pre‑market trading. The company also ended a prior $150 million at‑the‑market offering that had not sold any shares. These moves add to the company’s ongoing effort to fund its Phase 3 development program.